Key data
| Regulation | Decision (EU) 2026/1682 of the European Parliament |
|---|---|
| Publication | 10 September 2026 |
| Entry into force | 29 April 2026 |
| Affected parties | Companies and researchers participating or seeking to participate in projects funded by the EU's Innovative Health Initiative (IHI) |
| Category | European Regulation |
| Audited exercise | 2024 |
| Body | Joint Undertaking for the Innovative Health Initiative (IHI) |
| Result | Approval without serious irregularities detected |
If your company operates in the healthcare, pharmaceutical or medical technology sector and accesses—or wants to access—European funding for R&D projects, Decision (EU) 2026/1682 of the European Parliament is of interest to you. Approved on 29 April 2026 and published on 10 September 2026, this decision certifies that the Joint Undertaking for the Innovative Health Initiative (IHI) correctly executed its budget during the 2024 financial year.
It is not a regulation that imposes new obligations or sanctions. It is the mechanism of democratic control—technically known as discharge—by which the European Parliament oversees how community funds have been spent. And the verdict for 2024 is positive: management approved, without serious irregularities.
What does this regulation establish?
The IHI is a public-private partnership of the EU that brings together the European Commission with the European pharmaceutical and healthcare industry. Its mission is to accelerate the development of new treatments, diagnostic tools and health solutions through co-financing of research and development projects.
The discharge procedure is the annual mechanism by which the European Parliament reviews whether bodies managing community funds have done so correctly. If approval is granted—as in this case—it means that:
- No serious irregularities were detected in the execution of the IHI's 2024 budget.
- European funds allocated to health R&D projects were managed in accordance with community rules.
- The program maintains its status as a reliable body for receiving and distributing European public funding.
This act does not modify any previous regulation nor introduce new requirements for beneficiaries. It is an institutional validation of the already closed financial year.
Economic and operational impact
For companies already participating in IHI projects, the approval of the 2024 accounts has a direct but indirect impact in economic terms:
- Legal certainty: Payments and co-financing received in 2024 are institutionally validated. There is no risk of review or claims arising from irregularities in the management of the body.
- Program continuity: Approval strengthens the stability of the IHI as a funding vehicle. Future calls are not at risk due to governance problems.
- Signal for new participants: Companies evaluating whether to apply for IHI calls can interpret this approval as a guarantee that the program operates with transparency and control.
From an operational perspective, there are no changes in the procedures for application, justification or audit of IHI projects resulting from this decision. The framework for participation remains as established in the IHI's constitutive regulation.
Who does it affect?
- Pharmaceutical companies participating or having participated in projects co-financed by the IHI in 2024.
- Medical technology and diagnostics companies with active or in-preparation projects under IHI calls.
- Research centers and hospitals collaborating with industry in IHI consortia.
- Startups and SMEs in the healthcare sector evaluating whether to apply for future IHI calls.
- CFOs and financial directors responsible for justification and audit of European funds received through the IHI.
- Advisors and consultants supporting companies in the management of R&D projects with European funding.
Practical example
Imagine a Spanish biotechnology company that in 2023 joined a European consortium funded by the IHI to develop a new early diagnostic tool for neurodegenerative diseases. During 2024, the company received payments from the IHI as part of the project's co-financing.
With the approval of the 2024 accounts by the European Parliament, this company obtains institutional confirmation that the funds received were managed correctly at the level of the funding body. This means:
- There will be no extraordinary audits or claims arising from problems in the management of the IHI.
- The project can continue normally in 2025 and 2026 without uncertainty about the stability of the program.
- If the company was evaluating whether to apply for a new IHI call, this approval eliminates the risk that the program is under negative scrutiny.
What should companies do now?
- If you participate in active IHI projects: Verify that your company has up-to-date documentation for justifying expenses for the 2024 financial year. Institutional approval does not exempt you from project-specific audits.
- If you are preparing an application for IHI calls: Interpret this approval as a green light on the stability of the program. Continue with the process of identifying open calls on the official IHI portal.
- If you are a CFO or financial manager: Document this approval internally as evidence of the solidity of the funding body for your risk and internal audit reports.
- If you advise healthcare sector companies: Communicate to your clients that the IHI program maintains good governance and that future calls are not compromised by management problems.
- Keep regulatory monitoring: Although this decision does not impose new obligations, IHI calls and participation requirements may be updated. Regularly review the official IHI portal and the EU Official Journal to stay up to date.
Frequently asked questions
What does it mean that the European Parliament approves the IHI 2024 accounts?
It means that the mechanism of European democratic control—called discharge—has verified that the Joint Undertaking for the Innovative Health Initiative executed its 2024 budget without serious irregularities. It is an institutional validation that confirms the good governance of the program and the correct management of community funds allocated to health R&D.
Does this approval affect the audits of my IHI project?
Not directly. The approval of the body's accounts (discharge) is independent of the individual audits of each project. Your company remains obligated to correctly justify the expenses of its project according to the requirements of the grant agreement signed with the IHI. Institutional approval does not cover possible irregularities at the individual project level.
What is the IHI and how can it finance my company's projects?
The IHI (Innovative Health Initiative) is a public-private partnership of the EU that brings together the European Commission with the European pharmaceutical and healthcare industry. It co-finances R&D projects aimed at accelerating the development of new treatments and diagnostic tools. Companies can participate by responding to open calls published on the official IHI portal, generally as part of European consortia.
When did this decision enter into force and what is the timeframe for adaptation?
Decision (EU) 2026/1682 entered into force on 29 April 2026, the date it was adopted by the European Parliament. It does not establish any adaptation timeframe for companies, as it does not impose new obligations: it is an act of internal budget control by the EU, not a regulatory norm directed at the private sector.
What risk would it pose to my company if the IHI had irregularities in 2024?
If the European Parliament had detected serious irregularities and denied approval of the accounts, a review process could have been opened that would affect the continuity of the program, pending payments and the reputation of the body as a funder. In this case, approval without irregularities eliminates that risk and guarantees program stability for current and future participants.
Official source
Consult the complete regulation on official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202601682
